Aurinia Pharmaceuticals (NASDAQ:AUPH) has announced plans to present new data reinforcing the clinical significance of LUPKYNIS in the treatment of lupus nephritis (LN) at the American Society of Nephrology (ASN) Kidney Week 2024.
LUPKYNIS (voclosporin), a second-generation calcineurin inhibitor (CNI), is used to treat adult patients with active LN. Through the presentation of six abstracts, including five poster sessions, Aurinia will share study findings underscoring theimportant role that LUPKYNIS plays in preserving kidney function, while providing further evidence distinguishingLUPKYNIS from first-generation CNIs.
“The data featured at ASN elucidate the critical role LUPKYNIS plays in advancing the treatment of lupus nephritis, especially in populations disproportionately impacted by the disease. We’re particularly excited about moving our ENLIGHT-LN™ registry forward, as clinicians need insights into real-world treatment patterns. Additionally, we continue adding to our growing body of evidence that the unique mechanism of action of LUPKYNIS affects podocytes, resulting in significant impact on kidney health in adults with active LN,” said Dr. Greg Keenan, Chief Medical Officer of Aurinia.
